Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

3.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study.

Blood advances·2026
Same author

Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions.

American journal of clinical dermatology·2026
Same author

Safety of dermatologic surgery during immune checkpoint inhibitor therapy.

Journal of the American Academy of Dermatology·2026
Same author

Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.

Journal for immunotherapy of cancer·2026
Same author

Patient Perspectives regarding Artificial Intelligence-Driven Trichoscopy for Alopecia Evaluation.

Skin appendage disorders·2026

Related Experiment Video

Updated: May 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.7K

Lichen Sclerosus in Cancer Patients.

Amaris N Geisler1, Shivani Jain2, Kara Long Roche3

  • 1Department of Dermatology, Emory University School of Medicine, Atlanta, GA.

Journal of Lower Genital Tract Disease
|February 6, 2025
PubMed
Summary

Cancer therapies, particularly hormonal therapy, are associated with the development of lichen sclerosus (LS) in female patients. Management of LS during cancer treatment often requires escalating therapies due to unique challenges.

More Related Videos

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

369

Related Experiment Videos

Last Updated: May 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.7K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

369

Area of Science:

  • Dermatology
  • Oncology

Background:

  • Lichen sclerosus (LS) is a chronic inflammatory skin condition.
  • The association between cancer therapies and LS development is not well-established.

Purpose of the Study:

  • To characterize the association between cancer therapies and the development of lichen sclerosus (LS).
  • To analyze clinical and treatment characteristics of patients who developed LS during cancer therapy.

Main Methods:

  • Retrospective chart review of patients diagnosed with LS during cancer therapy at Memorial Sloan Kettering Cancer Center (2003-2019).
  • Exclusion of patients diagnosed with LS prior to cancer therapy.
  • Analysis of clinical and treatment characteristics.

Main Results:

  • 29 female patients developed LS during systemic cancer therapy.
  • Median time to LS onset was 420 days.
  • Breast cancer (34.5%) was the most common primary tumor; hormonal therapy (34.5%) was the most common regimen.
  • Most patients (69.6%) required escalated LS treatment beyond initial ultrapotent topical steroids.

Conclusions:

  • Hormonal therapy is a common cancer treatment associated with LS development.
  • Managing LS in cancer patients presents challenges due to overlapping pathophysiology and treatment mechanisms.
  • Limited data exists to guide LS treatment in this population, necessitating close follow-up for both conditions.